Jpmorgan Chase & CO Oncternal Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.29 - $0.48 $5,817 - $9,628	20,060 Added 74296.3%	20,087 $6,000
Q2 2022 Aug 11, 2022	SELL	$0.7 - $1.56 $14,528 - $32,377	-20,755 Reduced 99.87%	27 $0
Q1 2022 May 11, 2022	SELL	$1.37 - $2.43 $406 - $721	-297 Reduced 1.41%	20,782 $29,000
Q4 2021 Feb 10, 2022	SELL	$2.27 - $4.39 $45,202 - $87,418	-19,913 Reduced 48.58%	21,079 $48,000
Q3 2021 Nov 12, 2021	BUY	$3.37 - $4.76 $138,143 - $195,121	40,992 New	40,992 $171,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.